Centro para el Desarrollo de la Tecnología y la Innovación de España
Calle del Cid, 4, Madrid, Madrid, 28001, Spain
Overview
The Center for Industrial Technological Development (CDTI) is a public corporation under the Ministry of Economy and Competitiveness, which promotes innovation and technological development of Spanish companies. Is the entity which channels requests for funding and support to projects I + D + i of Spanish companies in the national and international levels. The CDTI has a staff of more than 300 people formed three quarters of engineers and graduates. Although the bulk of the infrastructure of the CDTI is located in Madrid, the Centre offers Spanish companies a strategic network of offices and representatives abroad (Japan -SBTO (Spain Business and Technology Office) - Belgium -SOST (Spain Office of Science and Technology) and Permanent Secretariat Eureka-, Brazil -FINEP (Financier of Studies and Projects) -, Korea, Chile, Morocco, China, India, Mexico and USA) to support them in their technological activities of type int .
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 1
- Active investors
- 4
Sector focus
- Finance
Investment portfolio
- Oncomatryx
Led · Equity · Mar 2026
ONCOMATRYX has developed a proprietary Antibody-Drug Conjugate (ADC) platform focused on targeting Cancer-Associated Fibroblasts (CAFs) in the microenvironment of metastatic solid tumors. The company uses AI tools and Quantum Computing to assist in ADC design and candidate selection and employs proprietary payloads, dual payload strategies, and conjugation chemistry within its ADC+ platform. Its lead candidate, OMTX705, is undergoing clinical development (Phase Ib-II) with results planned for presentation at major oncology conferences in 2026, and OMTX105 is being prepared for clinical entry. ONCOMATRYX conducts collaborations with universities, hospitals and research centers in the US and Europe and is developing an ADC Fill & Finish facility in San Sebastián. The company recently raised $67 million from a mix of public and private investors to advance its clinical programs and expand its pipeline.